Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifarizine SCHEMBL14809613 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| Lifarizine SCHEMBL2231142 | 0.99 | CYP3A4 (0.56) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL9146587 | 0.94 | LMNA (0.51) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL8989078 | 0.88 | CYP2D6 (0.48) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| Lifarizine SCHEMBL676318 | 0.84 | DRD2 (0.57) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL8963681 | 0.84 | CYP3A4 (0.53) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL8963806 | 0.83 | CYP3A4 (0.56) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| Lifarizine SCHEMBL8963776 | 0.83 | DRD2 (0.56) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL8963453 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL8963815 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP2C19CYP2C9NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | claimed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | claimed |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-24 | — | — | US | claimed |
| CN-109893528-A | Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness | 福建医科大学 | 2019-06-18 | — | — | CN | claimed |
| US-20170319517-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | THE GENERAL HOSPITAL CORPORATION | 2017-11-09 | — | — | US | claimed |
| US-20020040042-A1 | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma | ALLERGAN, INC. | 2002-04-04 | — | — | US | claimed |
| US-20020013353-A1 | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma | ALLERGAN, INC. | 2002-01-31 | — | — | US | claimed |
| US-6326389-B1 | ADMINISTERING SODIUM CHANNEL MODULATORS | ALLERGAN SALES, INC. | 2001-12-04 | — | — | US | claimed |
| EP-1011656-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | Head Explorer ApS (DK) | 2000-06-28 | — | — | EP | claimed |
| CN-1251520-A | Use of sodium channel blocker in manfacture of medicament for preventing optic nerve degeneration associated with glaucoma | ALLERGAN SALES INC (US) | 2000-04-26 | — | — | CN | claimed |
| EP-0973500-A1 | USE OF SODIUM CHANNEL BLOCKER IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA | Allergan Sales, Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| US-5922746-A | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma | ALLERGAN (US) | 1999-07-13 | — | — | US | claimed |
| WO-1998043612-B1 | USE OF SODIUM CHANNEL BLOCKER IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA | — | 1998-11-12 | — | — | WO | claimed |
| WO-1998043612-A1 | USE OF SODIUM CHANNEL BLOCKER IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA | ALLERGAN SALES, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319517-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | CYP3A4 4526/4885CYP2C19 3786/4885CYP2C9 3257/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | CYP3A4 2316/4885CYP2C19 1886/4885CYP2C9 3070/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | CYP3A4 4368/4885CYP2C19 4625/4885CYP2C9 4155/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | CYP3A4 4337/4885CYP2C19 4330/4885CYP2C9 4573/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CYP3A4 4501/4885CYP2C19 4496/4885CYP2C9 3962/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | CYP3A4 4504/4885CYP2C19 4487/4885CYP2C9 3958/4885 |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | CYP3A4 4526/4885CYP2C19 3786/4885CYP2C9 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.